A detailed history of Freestone Grove Partners LP transactions in Abbott Laboratories stock. As of the latest transaction made, Freestone Grove Partners LP holds 918,608 shares of ABT stock, worth $117 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares
918,608
Previous 90,883 910.76%
Holding current value
$117 Million
Previous $12.1 Billion 936.36%
% of portfolio
0.94%
Previous 0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$123.95 - $138.08 $103 Million - $114 Million
827,725 Added 910.76%
918,608 $125 Billion
Q1 2025

May 15, 2025

BUY
$111.1 - $140.22 $10.1 Million - $12.7 Million
90,883 New
90,883 $12.1 Billion

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $224B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.